Applied Therapeutics, Inc.
APLTHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $455,000 | $10.0M | — | — | — | — |
| Operating income | −$104.3M | −$64.5M | −$83.0M | −$105.6M | −$94.5M | −$45.6M |
| Net income | −$105.6M | −$119.8M | −$82.5M | −$105.6M | −$94.0M | −$45.5M |
| Total assets | $86.7M | $54.8M | $38.4M | $89.9M | $104.5M | $48.4M |
| Total liabilities | $29.7M | $72.0M | $34.3M | $27.4M | $22.6M | $15.8M |
| Equity | $57.0M | −$17.1M | $4.1M | $62.5M | $81.9M | $32.6M |
| EPS (diluted) | $-0.76 | $-1.42 | $-2.18 | $-4.12 | $-4.28 | — |
| Shares out. | 105.9M | 48.1M | 26.2M | 26.0M | 22.0M | 18.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −22922.9%
- Net margin
- −23214.1%
- Return on equity
- −185.3%
- Return on assets
- −121.8%
- Return on capital (ROCE)
- −175.6%
- Liabilities / assets
- 34.2%
- Debt / equity
- 0.52×
- Book value / share
- $0.54
- Revenue growth (YoY)
- −95.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -23.40distress
- Accruals / assets
- −24.6%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 31, 2025
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Not Yet Recruitingreadout ~2025-10-17Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss
- EARLY_Phase 1Not Yet Recruitingreadout ~2026-10-19Pharmacokinetic Study of DA-020
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vestal Point Capital, LpPassive (13G)Feb 17, 2026
- Propel Bio Management, LlcPassive (13G)Dec 31, 2025
- Alexandria Real Estate Equities, Inc.Passive (13G)Dec 15, 2025
- T. Rowe Price Investment Management, Inc.Passive (13G)Nov 14, 2025
- Vanguard Group IncPassive (13G)Jul 29, 2025
- Blackrock, Inc.Passive (13G)Jul 16, 2025
- Venrock Healthcare Capital Partners Iii, L.P.Passive (13G)May 15, 2025
- Schonfeld Strategic Advisors LlcPassive (13G)May 15, 2025
- Janus Henderson Group PlcPassive (13G)Feb 14, 2025
- Alyeska Investment Group, L.P.Passive (13G)Feb 14, 2025
- Perceptive Advisors LlcPassive (13G)Feb 14, 2025
- Morgan StanleyPassive (13G)Feb 7, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Jan 30, 2026 | 1.5M | 1.0 | -59.0% |
| Jan 15, 2026 | 3.5M | 1.0 | -46.6% |
| Dec 31, 2025 | 6.6M | 1.0 | -55.5% |
| Dec 15, 2025 | 14.9M | 1.4 | +1.7% |
| Nov 28, 2025 | 14.6M | 1.0 | +20.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsFeb 3, 2026
- Entered a material agreement · New financial obligation · Regulation FD disclosureDec 12, 2025
- Other material eventNov 20, 2025
- Results of operations · Director / officer changeNov 13, 2025
- Entered a material agreement · Other material eventAug 29, 2025
- Other material eventAug 14, 2025
- Results of operationsAug 13, 2025
- Results of operations · Other material eventAug 12, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.